Breast carcinoma

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…

Researchers are studying giredestrant, an experimental daily pill, in people with estrogen receptor-positive, HER2-negative early breast cancer. The trial enrolls about 1,500 participants, including some who switch to giredestrant after other treatments. It tracks how many people…

Researchers are testing whether adding an experimental drug called HLX22 to standard trastuzumab and chemotherapy helps people with locally advanced or metastatic HER2-positive breast cancer that has already been treated with a HER2 ADC. About 90 adults will receive either HLX22 …

Researchers are testing whether women aged 65 and older with early-stage, lymph node-positive, ER+/HER2- breast cancer can safely skip chemotherapy. Participants receive CDK4/6 inhibitors, with or without endocrine therapy, after surgery. The trial tracks how many women remain fr…

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

Researchers at Mayo Clinic are studying a remote monitoring program called SHIELD for cancer patients who are starting systemic therapy. Participants use a smartphone app to report symptoms and wear a small temperature sensor. The app and sensor send data to the medical record, w…

Researchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…

This study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…

This study tests whether a patient navigator program can help breast cancer patients with social challenges—like food, housing, or transportation issues—stay on schedule with their treatment. Participants will be contacted by a navigator every three weeks to connect them with com…

This phase 1 trial is testing whether combining the experimental drug zotatifin with the chemotherapy carboplatin can help people with advanced triple-negative breast cancer (TNBC) that has not responded to standard treatments. The study aims to find the safest and most effective…

This trial compares an experimental drug called HB1801 with the standard chemotherapy docetaxel (Taxotere) in people with HER2-negative advanced breast cancer. The goal is to see whether HB1801 can delay cancer growth better than docetaxel. Participants receive either HB1801 or d…

This early-phase trial is testing whether a personalized cancer vaccine, made from a patient's own tumor, can safely boost the immune system's ability to fight triple negative breast cancer. About 30 newly diagnosed patients will receive the vaccine along with standard chemothera…

This phase II trial tests whether combining the hormone therapy letrozole with standard chemotherapy before surgery can improve tumor shrinkage in people with ER-positive, HER2-negative breast cancer that grows quickly. Participants receive either six cycles of docetaxel, epirubi…

This trial tests whether adding the investigational drug capivasertib to standard hormone-blocking therapy and a CDK4/6 inhibitor can improve treatment response in people with HR-positive, HER2-negative metastatic breast cancer. Participants receive either the standard treatment …

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This phase II trial tests whether a combination of culmerciclib, letrozole, trastuzumab, and pertuzumab can shrink tumors before surgery in people with HR-positive, HER2-positive early or locally advanced breast cancer. About 33 participants who have not had prior treatment will …

This Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…

This trial tests whether a culturally grounded supportive care navigation program can reduce emergency room visits, hospitalizations, and urgent care use among Hispanic/Latinx patients receiving cancer treatment. Participants are randomly assigned to either usual care or the inte…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead…

This phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…

This early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…

This phase 2 trial is investigating whether an experimental drug called SHR-A1811, given alone or followed by a standard combination therapy (THPy), can improve outcomes for women with stage II-III HER2-positive breast cancer before they undergo surgery. Participants first receiv…

This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…

This phase II trial is testing whether combining two drugs—sacituzumab govitecan, an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, and Q901, a targeted drug that blocks a key enzyme cancer cells need to divide—can shrink tumors in people with advanc…

This trial is testing whether giving a combination of immunotherapy (pembrolizumab) and chemotherapy before surgery can shrink or eliminate tumors in people with stage I triple-negative breast cancer. The study compares different treatment regimens to see which is most effective …

This trial tests whether adding an experimental immunotherapy drug (QL1706) to standard hormone therapy can shrink tumors in people with a common type of breast cancer (HR-positive, HER2-negative) that did not respond well to initial chemotherapy. About 40 participants whose tumo…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…

This trial is testing whether adding an experimental drug called JYP0035 to the standard medicine fulvestrant can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors have a PIK3CA gene mutation and who have already tried hormone t…

This trial is testing whether adding azeliragon, a RAGE inhibitor, to the drug T-DXd can help people with HER2-positive or HER2-low metastatic breast cancer whose cancer has progressed despite prior T-DXd treatment. The study will first find the safest dose of the combination, th…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…

This trial is testing whether the drug trastuzumab deruxtecan (T-DXd) can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors were originally classified as HER2-null (no HER2 protein) but were re-scored as HER2-ultralow using arti…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This trial is testing an investigational drug called SKB103 in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to see how well that dose shrinks tumors. Participants r…

This trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …

This trial is investigating whether cryoablation, a technique that freezes and destroys breast tumors with extreme cold, can be an effective alternative to surgery for certain patients. The study will include adults with localized breast cancer who cannot or choose not to have su…

This study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…

This early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…

This trial tests whether adding an immunotherapy drug called retifanlimab to two standard HER2-targeted therapies (trastuzumab and pertuzumab) can improve treatment response in people with HER2-positive breast cancer. The main goal is to see if the combination leads to a complete…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This trial tests whether a multimodal prehabilitation program—combining exercise, nutrition, and psychological support—can improve outcomes for patients with tumor-related bowel obstruction. Participants are randomly assigned to receive either this program plus postoperative immu…

This trial tests whether adding semaglutide to structured lifestyle counseling improves heart and blood vessel health in postmenopausal breast cancer survivors with obesity who are taking an aromatase inhibitor. Participants will receive either semaglutide or a placebo, along wit…

This phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…

This phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…

This trial tests whether simple reminders—sent to patients' phones and to their care teams—can increase the use of alcohol screening and brief counseling (SBIRT) during cancer care. About 315 adults with cancer across four clinics will take part, with some clinics using the remin…

This trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…

This trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…

This phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants …

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…

This phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…

This phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…

This phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…

This study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…

This trial tests whether a drug called trilaciclib can prevent myelosuppression — a drop in blood cell counts — caused by a type of chemotherapy known as topoisomerase I inhibitor antibody-drug conjugates (ADCs). About 96 cancer patients who are scheduled to receive these ADC dru…

This trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…

This study tests a drug called sacituzumab tirumotecan in 20 people with triple-negative breast cancer that has spread to the brain. The drug is given through a vein twice a month. The main goal is to see if it can shrink brain tumors. This is an early-phase trial, so it focuses …

This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…

This trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This phase II trial is testing whether a vaccine called STEMVAC can help prevent triple-negative breast cancer from coming back after surgery. The vaccine targets proteins that cancer cells use to grow and spread, aiming to boost the immune system to destroy any remaining tumor c…

This phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving…

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…

This phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This study explores whether cancer patients can safely receive proton radiation therapy while sitting upright instead of lying down. The upright system is already FDA-cleared, and the goal is to see if it works reliably for a range of patients. Researchers will track treatment su…

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

This study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …

This study tests whether adding lovastatin, a common cholesterol-lowering drug, can help the cancer treatment trastuzumab deruxtecan work better in people with HER2-low or ultralow advanced breast cancer. About 60 participants will receive both drugs to see if more tumors shrink …

This study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main go…

This phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…

This trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged …

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This Phase 3 trial compares two forms of the chemotherapy drug utidelone—a capsule taken by mouth versus an injection—both combined with another chemo drug, capecitabine, in people with HER-2 negative advanced breast cancer. The study aims to see if the oral capsule works as well…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients …

This pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alo…

This early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants acros…

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…

This early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is…

This study is testing whether some people with early-stage breast cancer can safely skip surgery after chemotherapy and instead use only radiation. It includes 84 adults with HER2-positive or triple-negative breast cancer who have responded well to initial chemo. The goal is to s…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

The SASHA trial is testing whether a single, high-dose radiation treatment delivered directly to the tumor site over one day is safe and effective for women with early-stage breast cancer. The study will enroll 134 women aged 40-85 who have already had a lumpectomy. Researchers w…

This study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer c…

This Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infu…

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …

This study looks at whether a structured support program can help people with early-stage, hormone-positive breast cancer stick to their ribociclib medication (taken with an aromatase inhibitor). About 90 participants will be split into two groups: one gets standard care, the oth…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This phase 2 trial is testing a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer that has stopped responding to endocrine therapy. T…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip breast and lymph node surgery. Half of the 150 participants will receive standard care including surgery, while the other half will have no sur…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aim…

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…

This study tests whether a new biosimilar drug, HLX319, works as well as the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either the biosimilar or the original drug before surgery to compare how th…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how …

This study tests two experimental drugs (SCTB41 and SCTB39-1) given together, sometimes with standard cancer therapy, in adults with advanced solid tumors that have not responded to prior treatments. The goal is to find safe doses and see if the combination can shrink tumors or s…

This study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the …

This study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before su…

This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 will take part. This is an early-stage trial, so th…

This study tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) in people with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the treatment shrinks tumors. About 24 adults…

This study tests a new type of breast-conserving surgery that uses a small camera inserted through a hidden armpit incision to remove tumors, compared to the standard open approach. About 1,366 women with early-stage breast cancer will be randomly assigned to one of the two surge…

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …

This study tests whether a drug called edaravone dexborneol can help people who have a stroke while also having active cancer. The drug is given by IV twice a day for 10-14 days. Researchers will check if it improves recovery and is safe. About 144 adults aged 18-80 will take par…

This phase 3 trial compares an injectable form of letrozole (given every 3 months) to the standard daily oral pill, both combined with ribociclib, in 300 postmenopausal women with advanced HR-positive, HER2-negative breast cancer. The goal is to see if the injection works as well…

This study tests whether adding the immunotherapy drug pembrolizumab to usual post-surgery treatment can help prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1,000 adul…

This study tests whether taking vitamin C and coenzyme Q10 can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 75 adults with various cancers who have not had chemo before will take these supplements alongside their treatment. The goal is to see i…

This phase 2 trial tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast cancer surgery can reduce the risk of the cancer returning. The study will include 760 women with triple-negative breast cancer who have had chemotherapy and…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This study tests whether taking letrozole, a hormone therapy pill, for one year before surgery can shrink tumors and clear cancer from lymph nodes in postmenopausal women with early-stage, hormone-sensitive breast cancer. All 126 participants will take letrozole daily and then ha…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrin…

This study looks at 4,000 women aged 50 or younger with a common type of early breast cancer. Researchers want to see if hormone therapy plus ovarian function suppression works as well as chemotherapy for those with certain genetic test scores. The goal is to find out who can saf…

This study tests whether monitoring tumor DNA in the blood (ctDNA) and treating with abemaciclib can prevent breast cancer from coming back. 30 people with HR+/HER2- breast cancer who have finished standard treatment will be followed. If ctDNA is detected, they will receive abema…

This phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how m…

This early-stage trial tests whether fecal microbiota transplants (FMT) from healthy donors can safely be added to standard chemotherapy and immunotherapy for triple-negative breast cancer. About 125 patients will take part, first in an observation phase and then in a treatment p…

This phase II trial is testing whether a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and tislelizumab (an immunotherapy)—can effectively treat early-stage triple-negative breast cancer with a less intense approach. The study will enroll 30 people and …

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will be randomly assigned to receive either chemo-im…

This study is testing whether people with certain non-invasive or early breast conditions (like ductal carcinoma in situ) can safely skip surgery and instead take hormone-blocking medication. The goal is to see if this approach keeps cancer from coming back over five years. The t…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests whether a combination of targeted drugs and hormone therapy can replace chemotherapy for people with a specific type of early-stage breast cancer (HR-positive, HER2-positive, no lymph node spread). About 1,500 participants will receive either the standard chemo p…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This early-stage trial tests a drug called sacituzumab govitecan combined with hormone therapy in 12 people with HR-positive, HER2-negative metastatic breast cancer that has worsened after CDK4/6 inhibitor treatment. The main goal is to check safety and side effects, while also l…

This early-stage trial tests whether freezing a breast tumor (cryoablation) before giving an immunotherapy drug (PD1 inhibitor) can help the immune system better recognize and attack triple-negative breast cancer. About 36 women with early-stage, high-risk breast cancer will rece…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly…

People with hormone receptor-positive, HER2-negative advanced breast cancer often start treatment with a CDK4/6 inhibitor plus an aromatase inhibitor. Over time, some tumors develop an ESR1 mutation that can make the aromatase inhibitor stop working. This study takes blood sample…

This study tests whether combining two lymph node biopsy methods, sentinel lymph node biopsy and wire localized lymph node biopsy, can accurately identify breast cancer patients with only limited lymph node spread. The goal is to see if these patients can safely skip a more invas…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This early-phase study tests a new radioactive imaging probe that targets a protein called FAP, found on many solid tumors. The probe is used with PET or SPECT scans to see if it can better locate tumors and determine if they have spread, compared to standard FDG-PET imaging. The…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This early-phase study tests a new radioactive tracer called [68Ga]Ga-FFD for PET imaging in healthy volunteers and people with solid tumors. The goal is to see if it is safe, where it goes in the body, and how well it spots tumors compared to standard imaging. Researchers will a…

This study will develop and test an AI model that combines MRI, ultrasound, digital pathology, and patient data to predict how well breast cancer responds to neoadjuvant therapy. Researchers will analyze data from 1,800 participants across multiple centers. The goal is to help do…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test if artificial intelligence can create clear breast MRI images without using contrast dye. Researchers will use a special type of MRI scan (diffusion-weighted imaging) to generate synthetic images that might help diagnose breast cancer. If successful, this cou…

This study tests whether a special ultrasound technique (super-resolution imaging) can predict if breast cancer will completely respond to chemotherapy after just one cycle. Researchers will enroll 150 women with invasive breast cancer scheduled for chemotherapy. The goal is to s…

This study tests an artificial intelligence (AI) system that analyzes breast images (digital breast tomosynthesis) to help doctors diagnose breast cancer more accurately. Researchers will train the AI on thousands of images from 5000 women to detect tumors, tell benign from malig…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study will test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately measure the size of breast tumors in people with ductal carcinoma in situ (DCIS). Twelve participants will receive both a standard MRI and an FCI scan before surgery. The results…

This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing e…

This study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…

This study tests a new type of PET scan using a tracer called 68Ga-FAPI-46 to find cancer that has spread in patients with lobular breast cancer. Standard scans often miss these metastases. The trial will enroll 45 adults whose standard PET scan was negative or unclear, and see i…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

Researchers at Vietnam National Cancer Hospital are testing whether adding one structured cognitive behavioral therapy (CBT) session to standard brief counseling helps cancer patients remain smoke-free. The trial enrolls 498 adults who smoked at cancer diagnosis and have stayed c…

This trial tests whether adding auricular acupressure—using small seed patches on specific ear points—to standard antiemetic medication can better prevent nausea and vomiting in people receiving highly emetogenic chemotherapy. About 332 patients with solid tumors will be randomly…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether providing online webinars, digital tools, and a logbook can help adults at high risk for breast cancer become more physically active. Participants (200 women aged 30-69) will either receive the full motivation package or just standard activity recommendat…

This study will test whether a 12-week program of supervised aerobic and strength exercises can prevent heart problems in 60 adults undergoing chemotherapy for cancer. Participants will be split into an exercise group and a usual-care group. Researchers will measure heart functio…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests a personalized program supported by a mobile app to prevent heart damage caused by breast cancer treatments. Researchers will enroll 102 women recently diagnosed with early-stage breast cancer who are at risk for heart side effects. The program uses artificial in…

This study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…

This study tests a surgical technique done at the same time as breast cancer lymph node removal to prevent arm lymphedema (chronic swelling). The procedure uses a small flap of tissue from the side of the chest to rebuild the armpit area and support fluid drainage. One hundred hi…

This trial tests whether a single, two-hour online class called Empowered Relief can help American Indian adults with cancer-related pain. Participants learn three pain relief skills, create a personal plan, and get access to a free audio app for daily practice. The study aims to…

Researchers at Dana-Farber Cancer Institute are testing Healing Gardens, a mobile game that delivers pain-focused cognitive behavioral therapy and cancer pain education. The study enrolls 46 adults with advanced solid tumors who have chronic pain related to cancer or its treatmen…

This study tests a spiritual health program called PATH for cancer patients struggling with feelings of disconnection, loss of meaning, or existential distress. Twenty adults with any stage of cancer will attend six workshops combining role-playing, psychology, and dignity therap…

Researchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…

Researchers test whether adding one structured cognitive behavioral therapy session to standard brief quit-smoking advice helps cancer patients stop smoking. The trial enrolls 446 adults with cancer in Vietnam who smoked at diagnosis and still smoke. Everyone gets brief counselin…

Researchers are testing whether mandala coloring can improve quality of life for people receiving cancer care. The trial enrolls 76 hospitalized cancer patients and assigns them to either a coloring group or a routine-care group. For three weeks, the coloring group uses a mandala…

Researchers at City of Hope test whether a prehabilitation program is practical for breast cancer patients receiving chemotherapy before surgery. The program includes aerobic exercise, nutrition guidance, and education, all led by a physiatry team. Twenty participants will be ask…

Researchers are testing whether a 12-week supervised dance-based exercise program can reduce cancer-related fatigue in women with newly diagnosed breast cancer who are having treatment before surgery. The study includes 104 women aged 18 to 60 who will be randomly assigned to eit…

This trial tests whether adding a donor nerve graft during implant-based breast reconstruction helps women regain breast and nipple sensation after nipple-sparing mastectomy. Each participant has one breast randomly chosen to receive the graft, while the other breast serves as a …

This trial tests whether cosmeceutical moisturizers can ease skin dryness in people with cancer who experience skin side effects from treatments like chemotherapy or immunotherapy. Participants apply the moisturizers daily for 2-4 weeks and report changes in dryness severity. The…

This pilot trial tests whether a program of virtual ukulele lessons, called STRUM, can help teenagers preserve cognitive function and emotional resilience while undergoing radiation therapy for cancer. The study enrolls adolescents aged 12 to 17 who are receiving initial radiatio…

This study will test whether a mobile app called RestoreMe can help cancer patients get personalized nutrition and activity advice. Researchers plan to enroll 150 adults who are about to start, are currently receiving, or have completed cancer treatment. Participants will use the…

Researchers are testing a digital tool called Mindbot, a chatbot on the LINE messaging app that guides hospitalized cancer patients through a 10-minute mindfulness session with breathing exercises and virtual reality. The trial enrolls 66 adults with cancer who are staying in the…

This trial tests whether progressive muscle relaxation, a technique where you tense and then relax different muscle groups, can lower anxiety in parents who are the primary caregivers of children with cancer. Researchers will randomly assign 112 parents to either join relaxation …

Researchers are testing whether a web-based game that teaches sleep hygiene can improve sleep quality and reduce fatigue in people receiving chemotherapy. The trial enrolls 56 adults undergoing chemotherapy who do not have a diagnosed sleep disorder. Half receive the gamified Sle…

This pilot study tests whether adding a specialized radiation technique called Lattice Radiation Therapy (LRT) to standard palliative radiation can safely shrink large tumors (at least 4.5 cm) in adults. The study will enroll 25 people with various cancers who are already schedul…

This pilot study tests whether changing the diet can improve gut health and help people with solid tumors recover from immune-related side effects caused by immune checkpoint inhibitor treatment. Participants are randomly assigned to eat a high-fermented food diet or take a resis…

This pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…

Researchers are testing two behavioral programs to help Hispanic cancer survivors with insomnia. One combines gentle movement, meditation, and breathing. The other uses cognitive behavioral therapy for insomnia. Both are being culturally adapted with input from survivors. The stu…

This study tests whether THC (with or without CBD) can improve sleep in people with solid organ cancer who have insomnia. About 69 participants will receive either THC, a THC/CBD mix, or a placebo as a liquid under the tongue. The goal is to see if these cannabis-based compounds …

This study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…

This study tests whether a four-week online yoga program, tailored to each teen's physical limits, can lower anxiety in adolescents aged 12 to 18 who are being treated for cancer. Participants either join the yoga sessions or receive no extra intervention, and researchers measure…

This study tests whether a smartphone app called the Cancer Exercise app (CEA) can help cancer survivors become more physically active. About 750 adults who have finished cancer treatment will either use the app for 12 weeks or receive usual care. The goal is to see if the app bo…

This study looks at whether adding the drug bupropion (Wellbutrin) to standard hormone therapy can help women with early-stage breast cancer who have lost interest in sex. About 100 women will be randomly assigned to receive either their usual hormone therapy alone or with buprop…

This study tests a group therapy program called LiveWell mBC for women with metastatic breast cancer who are feeling distressed. The program uses adapted Dialectical Behavioral Therapy (DBT) skills to help manage emotions and uncertainty. 48 women will be randomly assigned to eit…

This trial tests whether an inpatient yoga therapy program can improve quality of life and reduce symptoms like nausea, fatigue, and pain in cancer patients undergoing stem cell transplantation. Participants will be randomly assigned to either the yoga program or an enhanced stan…

This study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational su…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…

Many cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and …

This study is testing a family-centered program called SHINE, designed to support teenagers aged 10 to 17 who have a parent diagnosed with cancer. The program includes about four sessions over eight weeks, focusing on cancer education, family communication, coping skills, and emo…

This trial tests whether a type of talk therapy called Acceptance and Commitment Therapy (ACT) can help cancer survivors and their spouses cope with the fear that cancer might return. It compares ACT to a more traditional therapy, Cognitive Behavioural Therapy (CBT), in a two-arm…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This pilot trial tests whether a chatbot powered by large language models can help adolescent and young adult cancer survivors address reproductive concerns. Participants will be randomly assigned to use the chatbot or read an electronic brochure with similar information. The stu…

This pilot study tests whether a group telehealth session led by a palliative care pharmacist can help cancer patients better understand and manage their opioid pain medications. Many patients struggle with side effects, complex dosing, and fear of addiction, which can lead to un…

This trial tests whether a communication and care coordinator (CCC) can improve serious illness conversations and quality of life for adults with advanced or high-risk cancer. Participants in the intervention group will have six structured sessions over three months to discuss th…

This study tests two support programs for women aged 65 and older with hormone-sensitive breast cancer who are taking aromatase inhibitors. The programs include a clinic-level geriatric assessment and support, and a telehealth coping skills training based on cognitive behavioral …

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests whether a guided digital program delivered through a mobile app can reduce anxiety and depression in young adults (ages 18–40) who have fertility-related distress after a cancer diagnosis. Participants use the app to complete four modules covering coping skills, …

This trial compares two simple treatments—sucking on ice chips or using a lidocaine spray—to see which better prevents or reduces painful mouth sores caused by chemotherapy. About 60 adults with cancer who are about to receive chemotherapy will be randomly assigned to one of the …

This study tests whether a traditional Chinese medicine patch placed on the belly button (Shenque acupoint) can reduce fatigue in cancer patients about to start radiotherapy. Eighty adults with cancer-related fatigue will receive either the real herbal patch or a sham patch daily…

This pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…

This trial investigates whether daily aromatherapy foot baths with lavender essential oil can help cancer patients manage pain, sleep quality, and fatigue. Over five days, one group receives a 20-minute foot bath with lavender oil, while a control group receives routine care only…

This trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…

This study tests whether an AI-assisted expressive writing program can reduce anxiety, emotional distress, and improve quality of life in adults receiving chemotherapy for any type of cancer. Participants are randomly assigned to either use the AI writing tool alongside their usu…

This study tests whether taking a high dose of whey protein after each workout helps breast cancer survivors gain more muscle and lose more fat compared to exercise alone. Participants are women aged 20 to 89 who have completed treatment for breast cancer and are prescribed exerc…

This study tests whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting caused by antibody-drug conjugates (ADCs) in cancer patients. Participants are adults with malignant tumors who have never received ADCs before and are about to st…

This study will test a comfort menu and cart for older adults (60+) receiving cancer treatment at a hospital in Brazil. The cart offers items like blankets, pillows, and hygiene kits to improve comfort. Researchers will compare patient and staff experiences before and after the c…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study compares three techniques—ultrasound, wire, and magnetic seed—to help surgeons remove non-palpable breast tumors more accurately during breast-conserving surgery. About 1,300 adult women with early-stage breast cancer will be randomly assigned to one of the three metho…

This study tests a simple screening tool to identify cancer patients struggling with medical costs. Those who screen positive will be connected to financial counseling and resources at their hospital. The goal is to make it easier for patients to afford their care and reduce fina…

This study tests whether keeping older patients (65+) at a slightly higher body temperature (36.8°C) during major cancer surgery can reduce the risk of delayed neurocognitive recovery—a kind of short-term confusion or memory decline that can happen after surgery. About 1,500 part…

This study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…

This study tests whether a non-invasive technique called transcutaneous electrical acupoint stimulation (TEAS) can prevent or treat sleep problems after cancer surgery. TEAS uses mild electrical pulses on specific points on the skin, based on acupuncture, without needles. The tri…

This study will test a structured early rehabilitation program for women who have had breast cancer surgery. The program includes education, gentle exercises starting the day after surgery, and home-based workouts with monitoring. Researchers want to see if it is safe and helps w…

This study tests whether sophrology, a relaxation technique using gentle movements, breathing, and positive visualization, can reduce anxiety in cancer patients undergoing radiation therapy. Fifty-four adults with various cancers will be offered sophrology sessions during their t…

This study tests whether a supervised strength training program can improve quality of life, physical function, and mental health in children with cancer. Twenty participants under 18 who are currently on treatment or dealing with after-effects will do two 50-minute sessions per …

This study tests whether learning progressive muscle relaxation and deep breathing exercises can improve sleep for cancer patients receiving chemotherapy. About 40 adults aged 40-60 with poor sleep will be split into two groups: one gets relaxation training plus usual care, the o…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This observational study will follow 50 people receiving chemotherapy that often causes nausea and vomiting. Researchers want to see if those who use medical cannabis on their own have less nausea, better appetite, and fewer other side effects compared to those who don't use it. …

This study tests whether a 14-week personalized exercise program can improve mobility, strength, and quality of life in frail adults aged 65 and older with cancer who have recently been hospitalized. One hundred participants will either follow the adapted physical activity progra…

This study tests whether live, online group strength training can help older cancer survivors (age 65+) who have trouble with daily activities. 150 participants will be split into three groups: immediate strength training, delayed strength training, or stretching. The goal is to …

This study tests whether walking with a robot dog can improve sleep, reduce fatigue, and enhance quality of life in children aged 2-7 who are undergoing cancer treatment. Forty children will be randomly assigned to either robot-dog-assisted walks or usual care. The goal is to see…

This study tests whether a gentle electrical stimulation on the ear (called taVNS) can reduce joint and muscle pain caused by aromatase inhibitors, a common breast cancer treatment. 216 women with hormone-positive breast cancer will receive either real or sham stimulation daily f…

This study tests a new drug called INB301 in people with cancer who are losing weight and muscle (cancer cachexia). The goal is to see if it is safe and can help patients gain or maintain weight. About 146 adults with solid tumors like lung, pancreatic, or colorectal cancer will …

This study tests whether a specially designed AI chatbot can lower anxiety and trauma-related distress in adults recently diagnosed with cancer. Participants will use the chatbot for 12 weeks and complete surveys about their feelings and needs. The goal is to see if this digital …

This Phase 3 trial tests whether electroacupuncture—thin needles with mild electric pulses—can ease cognitive problems like memory loss and trouble focusing in cancer survivors. 168 participants will be assigned to real electroacupuncture, sham (fake) acupuncture, or a waitlist. …

This study tests whether a daily 50mg dose of sildenafil (Viagra) can prevent or reduce the fatigue and cognitive problems (brain fog) that often come with cancer treatment. The trial will enroll 30 women with ER+/HER2- breast cancer, aged 30-50, and track their symptoms using qu…

This study tests whether training doctors in shared decision-making and giving patients educational materials improves treatment conversations for HER2-negative metastatic breast cancer. 120 patients starting first-line therapy will be randomly assigned to receive the program or …

This study tests whether a 6-week gardening and nutrition program can improve quality of life for cancer survivors. Fifteen participants will attend weekly group sessions with gardening, cooking demos, and mindfulness. The main goal is to see if the program is practical and liked…

This study tests a group-based program for people with cancer that focuses on managing energy, doing meaningful activities, and improving quality of life. About 30 adults with cancer will take part in workshops and hands-on sessions in a community setting. The goal is to see if t…

This study tests whether silkworm pupa tablets can improve nutrition and reduce muscle loss (sarcopenia) in people who have completed cancer treatment. 480 participants will receive either the tablets or a placebo for 3 months. The main goal is to see if muscle strength and mass …

This study tests a new surgical approach for women with early breast cancer who need a nipple-sparing mastectomy. If cancer is found in the nipple during surgery, doctors will remove the nipple but try to save the pigmented skin around it (the areola) and rebuild a new nipple rig…

This study tests a new drug called PDC-1421 to see if it is safe and helps with depression in people who have cancer. About 12 adults with mild to severe depression and stage I-III cancer will take the drug for up to 5 weeks. Doctors will check mood changes using a standard depre…

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scann…

This study explores whether equicoaching—a type of coaching with horses—can help young adults (ages 15-25) who finished cancer treatment feel more confident and reconnect with others. Ten participants will take part in the program and share their experiences through interviews an…

This study tests whether a supervised exercise program combining resistance training and walking can improve physical function, fitness, and quality of life in women with stage IV breast cancer. 78 women currently on medical treatment will be randomly assigned to either the exerc…

This study tests whether a whole food, plant-based diet combined with behavioral education can improve quality of life and diet adherence in 60 women with metastatic breast or endometrial cancer. Participants are randomly assigned to either the plant-based diet with support or a …

This study tests whether a digital platform called Beacon can help doctors better manage symptoms in people with advanced cancer. About 40 patients will wear smartwatches and answer questions about how they feel. The platform combines this data to give doctors a clearer picture o…

This study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health issues. About 96 women will take part in group video sessions or receive an informational booklet. The goal is to see if the program improves sexual …

This study tests a digital exercise program called EMPOWER for children aged 3 to 6 who are undergoing cancer treatment. The goal is to see if the program can help them stay physically active, improve their motor skills, and boost their quality of life. Parents and nurses will al…

This study tests whether acupuncture can safely reduce hot flashes in women with hormone receptor-positive breast cancer who are on hormone therapy. Sixty patients will receive either real or sham acupuncture three times a week for eight weeks, then be followed for 16 more weeks.…

This study tests whether a cannabis extract oil containing THC and CBD can reduce the overall symptom burden in people with advanced solid tumors who are already taking strong painkillers. About 156 participants will receive either the cannabis oil or a placebo for 8 weeks. The m…

This study tests whether a personalized diet can improve quality of life in 100 women with advanced gynecologic or breast cancer who are receiving antibody-drug conjugate therapy. Participants will either follow a diet tailored to their needs or receive general Mediterranean diet…

This study tests whether giving atropine before treatment can prevent diarrhea in people with advanced breast cancer receiving the drug sacituzumab govitecan. About 30 participants will receive atropine alongside their cancer therapy. The goal is to improve treatment tolerance an…

This pilot study tests an online program called Finding My Way-UK for people who finished curative cancer treatment in the past year. The program includes six self-guided modules on coping, emotions, and body image. Researchers will check if it's easy to use and if it helps with …

This study tests whether virtual reality (VR) exercises can improve memory and thinking in cancer patients who have cognitive problems. 64 participants will either use a VR program or receive standard care. The goal is to see if VR can help with brain fog and improve quality of l…

This phase 3 trial tests whether CBD oil can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for early breast cancer. About 130 participants will receive either CBD or a placebo for 12 weeks, then switch treatments. The study measures pain interference …

This study compares removing drainage tubes earlier versus later after a specific type of nipple-sparing mastectomy with immediate breast implant reconstruction. About 379 women aged 18–70 with breast cancer or those having preventive mastectomy will take part. The goal is to see…

This study compares two types of nipple-sparing mastectomy: one done with a robotic arm through a small side incision, and the standard open surgery. Researchers want to see if the robotic method improves women's satisfaction, body image, and recovery over 12 months. The trial wi…

This study tests a simple home questionnaire for women with HR+HER2- advanced breast cancer who are taking CDK4/6 inhibitors and hormone therapy. The goal is to see if the questionnaire can accurately identify which patients truly need to come to the hospital for a check-up, pote…

This trial tests whether a smartphone app can help people improve their fitness before cancer surgery. 60 adults scheduled for elective cancer surgery will either use the app or receive usual care. The app guides them through weekly walking tests, daily check-ins on exercise, nut…

Researchers in Korea are reviewing medical records from about 2,000 patients with triple-negative breast cancer who received pembrolizumab plus chemotherapy before surgery. The study measures how many patients had no detectable cancer left in their breast and lymph nodes at surge…

This study will test whether cancer patients receiving chemotherapy and radiation therapy can use wearable health devices, like fitness trackers, to monitor their heart rate and activity levels. Twenty adults will wear the device during treatment and for four weeks after, uploadi…

This study collects tumor tissue and blood samples from 120 cancer patients who are receiving or will receive immunotherapy. The samples will be stored in a biobank for future research to better understand how these treatments work. No direct treatment is given; the goal is to ga…

This observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…

This study tests whether a machine learning model called PROTEGER can help doctors choose the right cancer treatment for adults aged 65 and older with solid tumors. Researchers will train the model on past patient data, then check its accuracy in a new group of patients across Ch…

This study surveys 240 breast cancer patients to understand how they use herbs and supplements alongside standard treatments like chemo or hormone therapy. Researchers want to see if ethnicity influences which products people take. The goal is to gather information, not to test a…

This pilot study tests whether surgeons will use a new set of timeline-specific guidelines designed to improve functional recovery after high-risk abdominal cancer surgery. Researchers will monitor how often surgeons follow the guideline in clinic. The goal is to see if such a to…

This study aims to understand what might cause breast cancer in men by collecting genetic, environmental, and lifestyle information from 120 male volunteers who are relatives of male breast cancer patients. Participants will fill out a questionnaire and provide a blood sample for…

This study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…

This observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults b…

This observational study looks at whether different molecular subtypes of breast cancer—like Luminal A, HER2-enriched, and triple-negative—show distinct patterns of bone metastasis on bone scans. Researchers will compare imaging results from 100 adults with breast cancer to see i…

This study tests whether a short educational presentation about radon can improve knowledge and encourage testing among cancer survivors, their caregivers, and family members. Participants attend a single session, either in person or online, led by a study staff member. The goal …

This study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…

This study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, wh…

This study asks whether adding overall survival data to standard progression-free survival information helps current or former cancer patients more accurately judge a new drug's survival benefit. Around 3,000 U.S. adults with a past or present cancer diagnosis will read about a h…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…

This study will enroll 235 women with hormone receptor-positive, HER2-negative breast cancer who are taking abemaciclib after surgery. Researchers want to see if higher levels of the drug in the blood are linked to severe diarrhea, a common side effect. By understanding this link…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study explores whether cancer patients undergoing treatment can use a smartwatch and smartphone surveys to report their quality of life and physical activity. Over 12 weeks, participants wear a smartwatch at least 10 hours a day and complete questionnaires at several time po…

This study enrolls 1,000 adults with solid tumors, including breast cancer, who receive an AI-based pathology test as part of their routine care. Researchers will link the AI test results with short- and long-term health outcomes to see how well the scores predict prognosis and t…

This study investigates whether different types of exercise can help middle-aged women reduce their body burden of PFAS (environmental chemicals) and improve muscle function. Participants will be assigned to either interval walking or high-intensity circuit training for six month…

This study looks at how the health of older adults with cancer affects the quality of life of the people who care for them. Researchers will follow 116 patient-caregiver pairs for six months, using questionnaires to measure caregiver well-being and patient frailty. The goal is to…

This study will collect blood samples from 100 adults with cancer who are starting immunotherapy. Researchers will analyze the samples to find patterns in immune cells and molecules that might predict how well the treatment works or if it causes side effects. The goal is to bette…

This study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…

This study tests an AI-powered chatbot that automatically creates personalized survivorship care plans for adult cancer survivors. The chatbot uses information from electronic health records to generate a plan and answer patients' questions about it. Researchers want to see if th…

This pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…

This study collects health data from Apple Watches and iPhones of 1,200 cancer patients to build a research database. The goal is to see if wearable data like activity and heart rate can help personalize cancer prognosis and treatment. Participants must have an Apple Health app a…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…

This study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning…

This study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…

This study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during tr…

This study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a s…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…

This study looks at how feeling overwhelmed by information and dealing with symptoms affects the sense of empowerment in 300 adult cancer patients getting outpatient chemotherapy. Researchers will use surveys to measure information overload, symptom severity, and empowerment leve…

This study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions abou…

This study will enroll 56 women with breast cancer to see if two different regional anesthesia techniques (paravertebral block vs. erector spinae plane block) cause different immune responses during surgery. Participants will receive one of the two blocks along with general anest…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study tests whether taking omega-3 supplements before surgery can change the types of fats found in breast tumors. About 35 adults with early-stage breast cancer will take the supplement for 4 to 28 weeks while also receiving standard cancer treatments. The goal is to see if…

This study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months…

This study looks at the best ways to add supervised exercise programs into standard cancer care. Researchers will track how often doctors refer patients to exercise and how many patients take part. The goal is to see if this approach is practical and helps improve patients' physi…

This large observational study will follow 4,000 young cancer survivors (ages 15-39) across Europe to understand how different cancer treatments impact fertility, hormone function, and pregnancy outcomes. Researchers will also evaluate the safety and success of fertility preserva…

This study will follow 3,000 young women (ages 15-39) with cancer to understand how treatments like chemotherapy and immunotherapy impact their fertility, pregnancy outcomes, and quality of life. Researchers will also look at the safety and success of fertility preservation metho…

This study will test an artificial intelligence system designed to give early warning of cancer spreading to other parts of the body. Current imaging can only see larger tumors, but this AI analyzes routine scans and patient data to detect signs of microscopic spread. Researchers…

This study follows 1,000 young men (ages 15-39) diagnosed with cancer to understand how treatments affect their fertility and hormone levels over time. Researchers will collect medical history, semen samples, and blood tests before and after therapy to identify who is at risk for…

This phase 2 trial is testing whether blood tests and imaging scans can tell if chemotherapy is working in people with early-stage triple-negative breast cancer before they go to surgery. The study will enroll 200 participants who will receive a combination of chemotherapy drugs …

This study is testing a new tool to help older adults (65+) with metastatic breast cancer and their care partners make treatment decisions together. Researchers want to see if the tool is acceptable, appropriate, and practical for use. The study involves 150 participants and focu…

This study looks at tumor samples from 55 women with early-stage breast cancer to find early signs of whether chemo-immunotherapy is working. By analyzing individual cells before, during, and after treatment, researchers hope to identify markers that predict response or resistanc…

This study will survey about 950 men who stored sperm at a French fertility center before cancer treatment between 2010 and 2024. Researchers want to know how many later became fathers, whether naturally or with medical help, and if they used their frozen sperm. The goal is to be…

This study aims to understand why breast cancer in young women is often more aggressive. Researchers will look at how pregnancy and breastfeeding might influence the disease. They will collect information from 1,000 women aged 45 or younger (and a comparison group aged 55+) with …

This study will track muscle deterioration in about 40 hospitalized cancer patients using simple tests like grip strength, electrical muscle readings, and body composition scans. Researchers hope to find patterns that help identify muscle loss early, which could lead to better su…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…

This pilot study tests whether a biology-guided therapy recommendations report can help doctors choose treatments for advanced hormone receptor-positive breast cancer that cannot be removed by surgery or has spread. Researchers will analyze tumor tissue from 20 patients to create…

This study will follow 2,200 young women (aged 40 or younger) who had breast cancer and carry a mutation in a breast cancer gene other than BRCA1/2. Researchers want to see if getting pregnant after diagnosis affects the cancer's return. The study does not test any drug or treatm…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study tests whether a new collimator (a filter that directs gamma rays) on a special camera can produce clearer whole-body images for cancer patients. About 18 adults with multiple known cancer lesions will receive standard scans using technetium-99m, lutetium-177, or iodine…

This study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…

This study looks at women with a very early form of breast cancer called DCIS. It uses a special test to find those at low risk of the cancer coming back. The goal is to see if these low-risk women can skip radiation therapy after their lump-removal surgery without a meaningful i…

This study looks at how diet and gut bacteria affect treatment outcomes in women with early-stage triple-negative breast cancer. Researchers will collect stool, blood, and tumor samples from 300 participants before, during, and after chemotherapy and immunotherapy. The goal is to…

This study looks at how adults getting chemotherapy use digital media and how well they understand online health information. Researchers will survey 80 patients about their digital habits and health literacy. The goal is to learn more so doctors can better support patients in us…

This study will collect data from 500 Danish cancer patients who need repeat radiation therapy (reirradiation). Researchers will track side effects, tumor control, and survival to build a database that can guide safer treatment in the future. The goal is to help doctors decide wh…

This study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovari…

This study aims to find blood markers that can predict which cancer patients will develop chronic nerve pain from chemotherapy. Researchers will collect blood samples and perform neurological exams on 192 patients over 6 months. The goal is to use this information to personalize …

This study looks at whether tiny particles called exosomes, released by breast cancer cells, contain genetic material (microRNA) that can predict how well chemotherapy will work before surgery. Researchers will collect tumor tissue and blood samples from 60 women with breast canc…

This study will test an AI-powered tool that analyzes tumor samples to help doctors choose the best treatment for people with triple-negative breast cancer. The tool looks at immune cells in the tumor to predict how well chemotherapy might work. The goal is to see if the tool can…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If…

This study will collect blood and swab samples from 160 adults with solid tumors who are about to start immunotherapy. The goal is to find a biological 'signature' that can predict which patients will develop severe immune-related side effects. If such a signature is found, it co…

This observational study looks at how having type 2 diabetes impacts quality of life in cancer patients receiving immunotherapy. Researchers will compare changes in well-being over six months between patients with and without diabetes. About 920 adults with solid tumors will fill…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…

This study will compare two different tissue expanders used in breast reconstruction after mastectomy in 80 women. Some participants will also receive radiation therapy, which is not typically recommended with these devices. Researchers will evaluate aesthetic outcomes, patient s…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires rem…

This study aims to better understand psychiatric disorders, thinking problems, and treatment side effects in 2000 cancer patients and their close relatives. Researchers will compare those with and without mental health issues to find patterns and improve care. No new treatments a…

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …

This study looks at stored tumor samples from 70 women with a common type of breast cancer (ER-positive, HER2-negative) who received hormone therapy. Researchers want to see if two specific proteins, p-AKT and p-S6, can help tell which cancers will respond to treatment and which …

This study will analyze medical records from 100,000 people in Korea who had early-stage hormone receptor-positive, HER2-negative breast cancer and received surgery followed by other treatments. The goal is to see how often the cancer comes back and what factors might affect that…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study will follow 45 cancer patients who use cannabis, asking them to log their use in a smartphone app. Researchers want to learn how often and why patients use cannabis, what forms they use, and what effects they notice. The goal is to gather real-world data to guide futur…

This study compares two types of scans—standard CT and bone scans versus PET-CT—to see which better evaluates how well the drug trastuzumab deruxtecan (T-DXd) works in people with HER2 low metastatic breast cancer. About 262 participants will be split into two groups and scanned …

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…